SARS-CoV-2 neutralizing antibodies after first vaccination dose in breast cancer patients receiving CDK4/6 inhibitors — Flora Zagouri (2021) | RDL Network
SARS-CoV-2 neutralizing antibodies after first vaccination dose in breast cancer patients receiving CDK4/6 inhibitors
Article 2021 en
Authors
FZ
Flora Zagouri
ET
Evangelos Terpos
OF
Oraianthi Fiste
Abstract
1 min read
Undoubtedly, the development of COVID-19 vaccines displays a critical step towards ending this devastating pandemic, considering their protective benefits in the general population. Yet, data regarding their efficacy and safety in cancer patients are limited. Herein we provide the initial analysis of immune responses after the first dose of vaccination in 21 breast cancer patients receiving cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors. The levels of neutralizing antibodies post vaccination were similar to the matched healthy controls, whereas no safety issues have been raised. Further exploration is needed to reduce the uncertainty of SARS-CoV-2 immunity among cancer patients under treatment.
Margherita Rosati, Evangelos Terpos, Mahesh Agarwal, Vangelis Karalis, Jenifer Bear, Robert Burns, Xintao Hu, Demetrios G. Papademetriou, Ioannis Ntanasis‐Stathopoulos, Ioannis P. Trougakos, Meletios A Dimopoulos, George N. Pavlakis, Barbara K. Felber
Discussion(0)
No comments yet. Be the first to comment.